Markets

DAX® – The wrestling goes into the next round – columns

Wednesday,
02.12.2020
08:35

from Jörg Scherer, Technical Analyst HSBC

| Views: 137

HSBC Daily Trading

The wrestling goes to the next round

After the extremely successful previous month, December got off to a good start. The bottom line is that the DAX® posted further price gains, which, as expected, bring the 13,400 point mark into focus. Tailwind continues to come from the USA, where, for example, the S&P 500® has reached a new all-time high (3,678 points). It is interesting in this country that yesterday’s DAX® trading range took place entirely within the previous day’s counterpart. So there is an inner bar. On the upside, the most recent high (13,445 points) can therefore be combined with the September high at 13,460 points to form the (possibly) decisive signal zone. If the leap over these hurdles is successful, an attempt at the previous all-time high of 13,795 points beckons. To the south, however, investors should have the low of the day before yesterday (13,257 points) in the back of their minds, especially since the German “blue chips” should probably take a break at the start of trading. A slide below this level would result in failure at the above. Speaking of the resistance zone at around 13,400 points and providing the starting signal for a short-term consolidation in the direction of the recent lows at 13,035 / 13,005 points.

DAX® (Daily)

Chart DAX®

Source: Refinitiv, tradesignal²

5-year DAX® chart

Chart DAX®

Source: Refinitiv, tradesignal²

New record high: triangles dissolved!

Gaps are important and often represent a significant source of performance. Gaps in prices that persist beyond the end of the period should therefore be procyclical, ie. H. interpret in the direction of the outbreak. Since the BioNTech share ultimately defended the gap of November 20 (USD 95.05 to USD 97.56), investors can tick the claim stated at the beginning. The jump to a new all-time high (USD 128.13) simultaneously ensures the “bullish dissolution” of two triangular formations. On the one hand, the price development of the last eight months can be interpreted as an ascending triangle. On the other hand, there has been a symmetrical counterpart since July (see chart). The latter opens up an imputed connection potential of up to around 140 USD. Under money management aspects, there is – depending on personal risk tolerance – either the upper limit of the above. ascending triangle in the form of the old record highs at USD 105 or the upward price gap described above as a hedge.

BioNTech (ADR) (Daily)

Chart BioNTech (ADR)

Source: Refinitiv, tradesignal²

5-year BioNTech (ADR) chart

Chart BioNTech (ADR)

Source: Refinitiv, tradesignal²

Are you interested in a daily delivery of our newsletter?

Subscribe for free

Important instructions
Advertising notice

HSBC Trinkaus & Burkhardt AG
Derivatives Public Distribution
Königsallee 21-23
40212 Düsseldorf

Free info line: 0800/4000 910
From abroad: 00800/4000 9100 (free of charge)
Hotline for consultants: 0211 / 910-4722
Fax: 0211 / 910-91936
Homepage: www.hsbc-zertifikate.de
Email: certificates@hsbc.de

2)Transaction costs and your custody account price (if any) are not taken into account in the presentation and have a negative effect on the performance of the investment.

Daily Trading – Technical Analysis
every trading day, free of charge

Daily trading offers a daily analysis of the DAX® and Euro-BUND-Future as well as further analyzes of stocks, currencies or indices.
For free subscription
More information at:
www.hsbc-zertifikate.de

Note:
PERSONAL-FINANCIAL.COM publishes analyzes, columns and news from various sources in this section.
PERSONAL-FINANCIAL.COM AG is not responsible for content that is recognizable by third parties in the “News” area
This website has been discontinued and does not adopt it as its own. These contents are in particular through
a corresponding “from” mark below the article heading and / or through the link
“To read the full article, please click here.” responsible for
this content is solely the named third party.

Other users were also interested in this article:

Tags

Related Articles

Back to top button
Close
Close